<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00364871</url>
  </required_header>
  <id_info>
    <org_study_id>NB201</org_study_id>
    <nct_id>NCT00364871</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Combination Therapy to Treat Uncomplicated Obesity</brief_title>
  <official_title>Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled Study of Combination Therapy for Safety and Efficacy in Subjects With Uncomplicated Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orexigen Therapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orexigen Therapeutics, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and safety of 3 combinations of&#xD;
      naltrexone and bupropion SR compared to naltrexone alone, bupropion SR alone or placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A completed proof of concept study, OT-101 (Data on File, Orexigen Therapeutics, 2005),&#xD;
      demonstrated that a combination of 300 mg bupropion SR and 50 mg naltrexone was associated&#xD;
      with greater weight loss than bupropion SR alone, naltrexone alone, or placebo in subjects&#xD;
      with uncomplicated obesity.&#xD;
&#xD;
      The hypothesis for the current trial is that by adjusting the doses and titration schedules&#xD;
      of bupropion SR and naltrexone greater efficacy and improved tolerability can be achieved. In&#xD;
      this trial, a higher dose of bupropion and 2 lower doses of naltrexone than utilized in the&#xD;
      previous trial (OT-101) will be evaluated. The doses of both drugs will be titrated over 4&#xD;
      weeks and administered twice a day. There are 2 cohorts. At each site, cohort 2 recruitment&#xD;
      began as soon as cohort 1 enrollment was completed. Cohort 1 treatment groups are (60 per&#xD;
      group):&#xD;
&#xD;
        -  Group 1: Bupropion SR (400 mg/day) plus Naltrexone (48 mg/day)&#xD;
&#xD;
        -  Group 2: Bupropion SR (400 mg/day) plus Naltrexone (16 mg/day)&#xD;
&#xD;
        -  Group 3: Bupropion SR (400 mg/day) plus N-Placebo&#xD;
&#xD;
        -  Group 4: B-placebo plus Naltrexone (48 mg/day)&#xD;
&#xD;
        -  Group 5: B-Placebo plus N-Placebo&#xD;
&#xD;
      Cohort treatment 2 Groups are:&#xD;
&#xD;
        -  Group 6: B-Placebo plus N-Placebo (n=20)&#xD;
&#xD;
        -  Group 7: Bupropion SR (400 mg/day) plus Naltrexone (32 mg/day)(n=60)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change in total body weight</measure>
    <time_frame>baseline to week 24</time_frame>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">410</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bupropion SR (400 mg/day) plus Naltrexone (48 mg/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bupropion SR (400 mg/day) plus Naltrexone (16 mg/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bupropion SR (400 mg/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Naltrexone (48 mg/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>B-Placebo plus N-Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>B-Placebo plus N-Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bupropion SR (400 mg/day) plus Naltrexone (32 mg/day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>naltrexone and bupropion SR</intervention_name>
    <description>naltrexone 16, 32 or 48 mg/day and bupropion SR 400 mg/day</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>6</arm_group_label>
    <arm_group_label>7</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female and male subjects, 18 to 60 years of age&#xD;
&#xD;
          -  Have body mass index (BMI) of 30 to 40 kg/m2&#xD;
&#xD;
          -  Free from clinically significant illness or disease as determined by medical history&#xD;
             and physical examination&#xD;
&#xD;
          -  Non-smoker and no use of tobacco or nicotine products for at least 6 months prior to&#xD;
             baseline&#xD;
&#xD;
          -  Normotensive (systolic &lt;140 mm Hg; diastolic &lt;90 mm Hg). Anti-hypertensive medications&#xD;
             are allowed with the exception of adrenergic blockers, beta-blockers and clonidine.&#xD;
             Medical regimen must be stable for at least 6 weeks&#xD;
&#xD;
          -  LDL cholesterol &lt; 190 mg/dL and triglycerides &lt; 400 mg/dL. Medications for treatment&#xD;
             of dyslipidemia are allowed as long as medical regimen has been stable for at least 6&#xD;
             weeks&#xD;
&#xD;
          -  No clinically significant abnormality of serum albumin, blood urea nitrogen,&#xD;
             creatinine, calcium and phosphorus&#xD;
&#xD;
          -  Bilirubin, ALT and AST within 1.5 x ULN&#xD;
&#xD;
          -  No clinically significant abnormality of hematocrit, white blood cell count, white&#xD;
             cell differential, or platelets&#xD;
&#xD;
          -  Fasting glucose less than 140 mg/dL on no hypoglycemic agents&#xD;
&#xD;
          -  No clinically significant abnormality on urinalysis&#xD;
&#xD;
          -  TSH within 1.5 x ULN, normal T3, if TSH below lower limit of normal&#xD;
&#xD;
          -  Negative serum pregnancy test in women with intact uterus&#xD;
&#xD;
          -  Score &lt; 11 for depression and score &lt; 11 for anxiety on Hospital Anxiety and&#xD;
             Depression (HAD) Scale&#xD;
&#xD;
          -  ECG: no clinically significant abnormality&#xD;
&#xD;
          -  Score of zero on the Mood Assessment questionnaire and a response of &quot;No&quot; to the&#xD;
             Bipolar Disorder Questions&#xD;
&#xD;
          -  If female with child-bearing potential, must be non-lactating and agree to use&#xD;
             effective contraception throughout the study period and 30 days after discontinuation&#xD;
             of study drugs&#xD;
&#xD;
          -  Able to comply with all required study procedures and schedule&#xD;
&#xD;
          -  Willing and able to give written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Obesity of known endocrine origin (e.g., untreated hypothyroidism, Cushing's syndrome)&#xD;
&#xD;
          -  Serious medical condition or medical condition that limits participation in the&#xD;
             prescribed exercise program: (e.g. unstable cardiovascular disease including&#xD;
             congestive heart failure, angina pectoris, and myocardial infarction; stroke;&#xD;
             claudication; acute limb ischemia; acute renal or hepatic disorder; renal, hepatic or&#xD;
             respiratory insufficiency)&#xD;
&#xD;
          -  Active malignancy or history of malignancy (other than non-melanoma skin cancer or&#xD;
             surgically cured cervical cancer) within 5 years of enrollment&#xD;
&#xD;
          -  Serious psychiatric condition (e.g., any history of bipolar disorder, psychosis,&#xD;
             suicidal attempt or post-partum depression; a history of major depression, suicidal&#xD;
             ideation or antidepressant use within 1 year)&#xD;
&#xD;
          -  Type I or Type II diabetes mellitus requiring pharmacotherapy&#xD;
&#xD;
          -  Excluded concomitant medications: anorectic agents; weight loss agents; dietary&#xD;
             supplements to promote muscle building, enhance mood, or reduce appetite; adrenergic&#xD;
             blockers; beta blockers; anti-psychotic agents; clonidine; theophylline; cimetidine;&#xD;
             oral corticosteroids; anti-depressant; topiramate; Depo-ProveraÂ®, smoking cessation&#xD;
             agents; frequent, known use of opioid or opioid-like analgesics&#xD;
&#xD;
          -  History of surgical intervention for obesity&#xD;
&#xD;
          -  History of seizure disorder or predisposition to seizures (e.g., history of&#xD;
             cerebrovascular accident, significant head trauma, brain surgery, skull fracture,&#xD;
             subdural hematoma, or febrile seizures)&#xD;
&#xD;
          -  History of bulimia or anorexia nervosa&#xD;
&#xD;
          -  History of drug or alcohol abuse within 5 years&#xD;
&#xD;
          -  History of treatment with bupropion, or naltrexone within 12 months&#xD;
&#xD;
          -  History of hypersensitivity to bupropion, or naltrexone&#xD;
&#xD;
          -  Use of drugs, herbs, or dietary supplements known to significantly affect body weight&#xD;
             within one month of baseline&#xD;
&#xD;
          -  Use of investigational drug, device or procedure within 90 days&#xD;
&#xD;
          -  Participation in any previous clinical trial conducted by Orexigen Therapeutics&#xD;
&#xD;
          -  Any condition which in the opinion of the investigator makes the subject unsuitable&#xD;
             for inclusion in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Greenway, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pennington Biomedical Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scripps Clinic Del mar</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSRA Partners in Health, Inc</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UK Clinical Research Organization</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennington Biomedical Research Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Nutrition and Preventive Medicine</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MUSC Weight Management Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <study_first_submitted>August 14, 2006</study_first_submitted>
  <study_first_submitted_qc>August 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2006</study_first_posted>
  <last_update_submitted>April 18, 2008</last_update_submitted>
  <last_update_submitted_qc>April 18, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2008</last_update_posted>
  <responsible_party>
    <name_title>Eduardo Dunayevich, MD</name_title>
    <organization>Orexigen Therapeutics, Inc</organization>
  </responsible_party>
  <keyword>Obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

